Eduardo Aguera-Morales

Profesor Asociado

Universidad de Córdoba

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Eduardo Aguera-Morales is an Associate Professor at Universidad de Córdoba, Spain. His research areas include multiple sclerosis, particularly focusing on evidence-based innovations in care, illness perception, and the economic burden of the disease. He has also published on advanced imaging techniques in neurological disorders and treatment responses in relapsing-remitting multiple sclerosis.

Articles (29)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (27)

Vilija Jokubaitis

MONASH UNIVERSITY

AUSTRALIA

Eduardo Aguera-Morales

Research Interests

Explore related searches

Contact this professor

About

Articles (29)

Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial.

Neurologists' Openness to Evidence-Based Innovation in Multiple Sclerosis Care: Individual and Structural Determinants.

Threatening illness perception and associated factors in early-stage relapsing-remitting multiple sclerosis.

Diffusion Tensor Imaging Study After Intraarterial Cell Therapy in Acute Ischemic Stroke: A Substudy of the IBIS Randomized Clinical Trial.

Diffusion Tensor Imaging Study After Intraarterial Cell Therapy in Acute Ischemic Stroke: A Substudy of the IBIS Randomized Clinical Trial

Economic burden of secondary progressive multiple sclerosis: DISCOVER study.

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

Attitudes of Neurologists Toward Serum Neurofilament Light-Chain Testing in the Management of Relapsing–Remitting Multiple Sclerosis with Cognitive Impairment

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.

Tandem CAR-T cell therapy: recent advances and current challenges.

Decompressive Hemicraniectomy without Evacuation of Acute Intraparenchymal Hemorrhage

Impact of Cognitive Impairment on Quality of Life in Multiple Sclerosis Patients—A Comprehensive Review

Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale.

Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.

Neuroprotective and antioxidant effects of docosahexaenoic acid (DHA) in an experimental model of multiple sclerosis

Comparative Study between the Diagnostic Effectiveness of Brain SPECT with [123I]Ioflupane and [123I]MIBG Scintigraphy in Multiple System Atrophy

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis.

[Family planning in men and women with multiple sclerosis. Analysis of the Andalusian Registry (2018-2022)].

Diagnostic Effectiveness of [123I]Ioflupane Single Photon Emission Computed Tomography (SPECT) in Multiple System Atrophy

Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach.

Recommendations for the coordination of Neurology and Neuroradiology Departments in the management of patients with multiple sclerosis.

Comparative effectiveness in multiple sclerosis: A methodological comparison.

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.

Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Untargeted metagenomic sequencing identifies Toscana virus in patients with idiopathic meningitis, southern Spain, 2015 to 2019

Sodium chloride-induced changes in oxidative stress, inflammation, and dysbiosis in experimental multiple sclerosis

Effect of the Mediterranean diet and probiotic supplementation in the management of mild cognitive impairment: Rationale, methods, and baseline characteristics.

Collaborators (27)

Vilija Jokubaitis

Luisa María Villar

Nick G Cunniffe

Camille Carroll

GRACIA MARIA QUINTANA-NAVARRO

Begoña Escribano Durán

Justin Yehuda Garber

Ana Maria Alonso Torres

Mark Slee

Marzena Pedrini

Alasdair Coles

Giovanna De Luca

Maria José Sá

William Brown

Javier Caballero-Villarraso

Marc Comas-Cufí

LAURA NAVARRO CANTO

Luis Brieva Ruiz

francesco patti

Alessandra Lugaresi

Guy Laureys

Marie D'hooghe

Izanne Roos

Allan Kermode

Joanna Siuda

Charles B. Malpas

William L Herring

Make your next move.